Ourobionics
Ourobionics is a Dutch deep-technology company that develops 4D biofabrication platforms — including the CHIMERA 5-in-1 device — and sensor-embedded human tissue models (notably UNIQUE-SKIN) for pharmaceutical, cosmetic, chemical, and Medtech customers seeking alternatives to animal testing.
- Company typePrivate
- Founded2021
- HeadquartersAmsterdam, Netherlands
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ourobionics does
Ourobionics is a Dutch deep-technology company founded in March 2021 and headquartered in Wageningen, The Netherlands. It develops 4D biofabrication technology that integrates human tissue engineering with embedded biosensors to produce "cyborganic" tissue constructs intended for preclinical drug and compound testing. The company targets four enterprise verticals — pharmaceutical, cosmetic, chemical, and Medtech — alongside academic and research institutions, with an explicit mission to replace animal testing, accelerate drug discovery, and lower pharmaceutical R&D costs.
The company's technological core is a patent-pending 3D bio-electric field biofabrication methodology licensed from University College London (UCL) and originated in Professor Suwan N. Jayasinghe's BioPhysics Group, whose underlying science is documented in over 150 scientific publications. This methodology is operationalized through CHIMERA, a 5-in-1 biofabrication device that integrates bio-electrospraying, cell-electrospinning, bio-electrojetting, melt-electrowriting, and conventional extrusion into a single platform with nanoscale resolution while preserving cell viability. The portfolio further includes UNIQUE-SKIN, a full-thickness in-vitro human skin model with epidermal and dermal layers, integrated hair follicles, sweat glands, and a functional vascular network, and a line of human-derived biomaterials — HumaDerm collagen, Huma OsteoGelatin, Huma OsteoGelMA, and HumaMatrix ECM — for tissue engineering applications.
Ourobionics operates three distinct revenue streams: capital sales of the CHIMERA device to academic and research institutes (pricing undisclosed), custom development of tailored tissue models for enterprise customers under direct engagement, and unit-priced sales of human-derived biomaterials through a company-owned e-commerce storefront at roughly €97–€635 per SKU. The company monetizes through one-time equipment and license sales rather than recurring subscriptions, with go-to-market executed via enterprise field sales, conference presence (TERMIS, ScSB), and direct digital channels. To date, capital has been raised exclusively through non-dilutive Dutch and EU grant programs — notably the NXTGEN HIGHTECH National Growth Fund initiative (a EUR 1 billion multi-project program running through 2030) and the EU REACT-EU-backed ION+2 fund managed by Oost NL — supplemented by strategic R&D co-development with partners including the Smart Biomaterials Consortium (SBMC), Burn Research Lab, Hair Science Clinic, CyboSense, and Health~Holland.
Ourobionics firmographics
Firmographics- Name
- Ourobionics
- Legal name
- Ourobionics
- Website
- https://ourobionics.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Ourobionics is a Dutch deep-technology company that develops 4D biofabrication platforms — including the CHIMERA 5-in-1 device — and sensor-embedded human tissue models (notably UNIQUE-SKIN) for pharmaceutical, cosmetic, chemical, and Medtech customers seeking alternatives to animal testing.
- Ownership category
- akta.pro rank
Ourobionics industry classification
Industry- Product category
- Biofabrication Technology
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- 3D Bioprinting & Biofabrication (HLAAAGAC)
- akta.pro secondary industries
- Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD), Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK), Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG)
Keywords
Where Ourobionics is headquartered
LocationHeadquarters
- HQ city
- Amsterdam
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
Ourobionics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- CHIMERA Biofabrication Device Sales: Sale of CHIMERA 5-in-1 biofabrication device to academic institutions and research institutes. CHIMERA v1.0 has been released and is available for academic institutes with special conditions for first ambassadors.
- Human Tissue Models: Development and production of tailored human tissue models with embedded sensors for pharmaceutical, cosmetic, chemical, and Medtech companies for drug/compound testing.
- Human-Derived Biomaterials: Sale of human-derived biomaterials including HumaDerm (collagen), Huma OsteoGelatin, and HumaMatrix products for tissue engineering and regenerative medicine research.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | HumaDerm Human Skin Collagen Type I, Lyophilized |
| Unit Pricing | Pay-as-you-go | HumaDerm Human Skin Collagen Type I, Solution |
| Unit Pricing | Pay-as-you-go | HumaDerm Human Skin Collagen Type I, Lyophilized, Insoluble |
| Unit Pricing | Pay-as-you-go | Huma OsteoGelatin Type A, Lyophilized, Medium Bloom |
| Unit Pricing | Pay-as-you-go | Huma OsteoGelatin Type A, Lyophilized, High Bloom |
| Unit Pricing | Pay-as-you-go | Huma OsteoGelMA Type A, Lyophilized, Medium Bloom |
| Unit Pricing | Pay-as-you-go | HumaMatrix, Native Human-Derived ECM, Solution |
| Unit Pricing | Pay-as-you-go | HumaMatrix, Native Human-Derived ECM, Lyophilized |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Ourobionics product offering
Product offeringCore offering
Ourobionics develops and produces human tissue models with embedded biosensors and the CHIMERA 5-in-1 biofabrication device, leveraging proprietary 3D bio-electric field technology to deposit cells and biomaterials into complex 3D matrices. The company also sells a line of human-derived biomaterials (HumaDerm, Huma OsteoGelatin, HumaMatrix) for tissue engineering and regenerative medicine applications, serving pharmaceutical, cosmetic, chemical, and Medtech customers.
Product overview
Ourobionics is a deep technology company in 4D Bioprinting that combines a core CHIMERA biofabrication platform with advanced tissue models and human-derived biomaterials. The CHIMERA platform serves as the foundational technology enabling five biofabrication approaches (Bio-electrospraying, Cell-electrospinning, Bio-electrojetting, Melt-electrowriting, and Extrusion) to create complex human tissues. The UNIQUE-SKIN product represents the company's advanced tissue modeling offering—a full-thickness human skin model with hair follicles, sweat glands, and vascular networks. Complementing these are Human-Derived Biomaterials including HumaDerm collagen products, Huma OsteoGelatin, Huma OsteoGelMA, and HumaMatrix for tissue engineering and regenerative medicine applications. The company operates primarily in the pharmaceutical, cosmetic, chemical, and Medtech sectors.
Differentiator
Problem solved
Functional benefit
Brands
- CHIMERA: 5-in-1 biofabrication device utilizing bioelectric field technology for depositing cells and biomaterials in complex 3D matrices enabling tissue formation. Features capabilities including bio-electrospraying, cell-electrospinning, bio-electrojetting, melt-electrowriting, and extrusion.
- UNIQUE-SKIN
- HumaDerm
- HumaMatrix
- Huma OsteoGelatin
- Huma OsteoGelMA
Products and services
- CHIMERA 5-in-1 Biofabrication Device In-house developed 5-in-1 biofabrication device that uses a patent-pending 3D bio-electric field to deposit cells and biomaterials in complex 3D matrices with nanoscale resolution, enabling high-throughput complex tissue formation. Designed for academic and research institutes, with ambassador pricing for first customers.
- UNIQUE-SKIN Full-Thickness Human Skin Model Next-generation full-thickness in-vitro human skin model featuring epidermal and dermal layers, integrated hair follicles, sweat glands, and a functional vascular network. Designed for preclinical drug testing, tissue therapeutics, and regenerative medicine research with planned biosensor integration.
- Custom Tailored Human Tissue Models Bespoke human tissue models with embedded biosensors developed for pharmaceutical, cosmetic, chemical, and Medtech companies for drug discovery, safety testing, efficacy testing, and new treatment development.
- HumaDerm Human Skin Collagen Type I Native human skin type I collagen available in Lyophilized, Solution, and Insoluble forms, offering excellent biocompatibility and structural integrity for tissue culture coating and tailor-made hydrogels in tissue engineering.
- Huma OsteoGelatin Type A First and only human bone gelatin available in Medium Bloom and High Bloom variants, offering high biodegradability and low toxicity for surface coating and hydrogel encapsulations in regenerative medicine applications.
- Huma OsteoGelMA Type A Metacrylated human gelatin for tuneable 3D hydrogels that cure under UV light with a photoinitiator such as Irgacure 2959, providing improved mechanical properties and stability of tissue constructs.
- HumaMatrix Native Human-Derived ECM Human-derived extracellular matrix that mimics the natural cellular environment, available in Solution and Lyophilized forms and ready-to-use as a coating agent or hydrogel component in tissue engineering and regenerative medicine.
Quantifiable outcome
- 90% of drugs tested on animals ultimately fail in human trials - Ourobionics aims to solve that bottleneck
- +2 more outcomes
Companies that use Ourobionics
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles3 records
Ourobionics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
Ourobionics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and flagship.
- Smart Biomaterials Consortium (SBMC)coreStrategic R&D partnership to accelerate development of UNIQUE SKIN - a next-generation in-vitro human skin model using the patented CHIMERA 3D bioprinter. SBMC provides laboratory infrastructure, analytical support, and facilities for testing and scaling up technology.
- Burn Research LabcoreEMARS project collaboration to develop hair-bearing skin constructs for improving treatment of deep wounds and hair loss. Burn Research Lab provides clinical expertise and research facilities.
- Hair Science CliniccoreEMARS project collaboration optimizing hair graft storage conditions, determining conditions for hair regeneration from stem cells, and incorporating stem cells into skin constructs.
- CyboSensecorePartner providing advanced biomarker bioelectronic biosensor technology integrated into the UNIQUE SKIN project for real-time monitoring capabilities.
- University College London (UCL)flagshipTechnology invented by Professor Suwan N. Jayasinghe at UCL, licensed to Ourobionics. The bio-electric field technology has been proven in over 150 publications from UCL's BioPhysics Group.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Ourobionics competitors and assessment
Company assessmentDirect peers
- MIMETAS: Dutch organ-on-chip company selling OrganoPlate products to pharma for drug screening. Directly competes with Ourobionics' UNIQUE-SKIN in preclinical human-tissue testing, with overlapping customer base and GTM motion.
- Regemat 3D: Spanish bioprinting hardware manufacturer offering modular 3D bioprinters and bioinks. Overlaps with Ourobionics on the CHIMERA device side of the business, serving academic and clinical regenerative medicine customers.
- Organovo: Pioneer in 3D bioprinted human tissue for preclinical drug testing. Competes head-to-head with Ourobionics in the pharma tissue-model use case and shares the same regulatory tailwind from animal-testing phase-out.
- BICO (formerly CELLINK): Swedish leader in bioprinting hardware and biomaterials. Sells bioprinters and bioinks to academic and pharma customers globally — directly overlapping with Ourobionics' CHIMERA device and HumaDerm biomaterial offerings. Most comparable peer on business model and customer base.
- TissUse: German company developing multi-organ-chip (MOC) platforms for substance testing. Comparable product–market fit in pharma/cosmetics preclinical testing and similar European footprint to Ourobionics.
- Emulate: US organ-on-chip platform using Organs-on-Chips technology for pharma drug development. Competes for the same pharma preclinical-testing budget as Ourobionics' tissue models, particularly in safety and efficacy testing.
- Aspect Biosystems: Canadian biotech using microfluidic 3D bioprinting to create functional human tissues for therapeutic and drug-discovery applications. Comparable modality (biofabrication platform + tissue products) and target customers.
- Poietis: French company commercializing laser-assisted bioprinting for tissue engineering and in-vitro models. Overlaps with Ourobionics on bioprinting-hardware-plus-tissue-models positioning, particularly for cosmetic and pharma applications.
Broad incumbents
- 3D Systems: Large industrial 3D printing incumbent that has explored bioprinting and regenerative medicine applications. Adjacent rather than direct — overlapping on hardware but not focused on Ourobionics' tissue-model niche.
- Stratasys: Global 3D printing leader with historical investments in bioprinting and medical applications. Comparable on the printing-hardware axis but broader portfolio and not specialized in tissue engineering like Ourobionics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Ourobionics social profiles
Digital presenceOurobionics compliance and trust
Trust signalCompliance1 record
Ourobionics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ourobionics leadership team
Management profileNumber of profiles
Profiles8 records
Ourobionics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ourobionics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ourobionics
What does Ourobionics do?
Ourobionics develops and produces human tissue models with embedded biosensors and the CHIMERA 5-in-1 biofabrication device, leveraging proprietary 3D bio-electric field technology to deposit cells and biomaterials into complex 3D matrices. The company also sells a line of human-derived biomaterials (HumaDerm, Huma OsteoGelatin, HumaMatrix) for tissue engineering and regenerative medicine applications, serving pharmaceutical, cosmetic, chemical, and Medtech customers.
Is Ourobionics a public or private company?
Ourobionics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Ourobionics founded?
Ourobionics was founded in 2021. It employs 1 to 10 people.
Where is Ourobionics based?
Ourobionics is headquartered in Amsterdam, Netherlands, in the Europe region.
How does Ourobionics make money?
Three revenue lines are on record. CHIMERA Biofabrication Device Sales are the primary driver. The others are human Tissue Models and human-Derived Biomaterials.
Who are Ourobionics's main competitors?
Direct peers on record are MIMETAS, Regemat 3D, Organovo, BICO (formerly CELLINK), TissUse, Emulate, Aspect Biosystems and Poietis. Broad incumbents are 3D Systems and Stratasys.
Does Ourobionics have an API?
No public API is recorded for Ourobionics.
What industry is Ourobionics in?
Ourobionics's product category is Biofabrication Technology. Its primary akta.pro industry code is HLAAAGAC, 3D Bioprinting & Biofabrication, with a secondary code of HLAAAGAD, Organoids & Organ-on-Chip (regenerative models). Its NAICS code is 339112 and its SIC code is 3841.